These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 30838709)

  • 1. Efficacy of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28.
    Papp KA; Reich K; Blauvelt A; Kimball AB; Gooderham M; Tyring SK; Sinclair R; Thaci D; Li Q; Cichanowitz N; Green S; La Rosa C
    J Eur Acad Dermatol Venereol; 2019 Jun; 33(6):1098-1106. PubMed ID: 30838709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.
    Reich K; Papp KA; Blauvelt A; Tyring SK; Sinclair R; Thaçi D; Nograles K; Mehta A; Cichanowitz N; Li Q; Liu K; La Rosa C; Green S; Kimball AB
    Lancet; 2017 Jul; 390(10091):276-288. PubMed ID: 28596043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: a pooled analysis of two randomized controlled trials.
    Blauvelt A; Sofen H; Papp K; Gooderham M; Tyring S; Zhao Y; Lowry S; Mendelsohn A; Parno J; Reich K
    J Eur Acad Dermatol Venereol; 2019 Dec; 33(12):2305-2312. PubMed ID: 31407394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial.
    Papp K; Thaçi D; Reich K; Riedl E; Langley RG; Krueger JG; Gottlieb AB; Nakagawa H; Bowman EP; Mehta A; Li Q; Zhou Y; Shames R
    Br J Dermatol; 2015 Oct; 173(4):930-9. PubMed ID: 26042589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64-week phase 3 study (reSURFACE 1).
    Igarashi A; Nakagawa H; Morita A; Okubo Y; Sano S; Imafuku S; Tada Y; Honma M; Mendelsohn AM; Kawamura M; Ohtsuki M
    J Dermatol; 2021 Jun; 48(6):853-863. PubMed ID: 33630387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis.
    Elewski B; Menter A; Crowley J; Tyring S; Zhao Y; Lowry S; Rozzo S; Mendelsohn AM; Parno J; Gordon K
    J Dermatolog Treat; 2020 Dec; 31(8):763-768. PubMed ID: 31268369
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies.
    Kimball AB; Papp KA; Reich K; Gooderham M; Li Q; Cichanowitz N; La Rosa C; Blauvelt A
    Br J Dermatol; 2020 Jun; 182(6):1359-1368. PubMed ID: 31487406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks.
    Reich K; Warren RB; Iversen L; Puig L; Pau-Charles I; Igarashi A; Ohtsuki M; Falqués M; Harmut M; Rozzo S; Lebwohl MG; Cantrell W; Blauvelt A; Thaçi D
    Br J Dermatol; 2020 Mar; 182(3):605-617. PubMed ID: 31218661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of bodyweight on the efficacy and safety of ixekizumab: results from an integrated database of three randomised, controlled Phase 3 studies of patients with moderate-to-severe plaque psoriasis.
    Reich K; Puig L; Mallbris L; Zhang L; Osuntokun O; Leonardi C
    J Eur Acad Dermatol Venereol; 2017 Jul; 31(7):1196-1207. PubMed ID: 28370467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tildrakizumab for the treatment of psoriasis.
    Sinclair R; Thirthar Palanivelu V
    Expert Rev Clin Immunol; 2019 Jan; 15(1):5-12. PubMed ID: 30394141
    [No Abstract]   [Full Text] [Related]  

  • 11. Long-term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 5-year extension of a phase 3 study (reSURFACE 1).
    Imafuku S; Nakagawa H; Igarashi A; Morita A; Okubo Y; Sano S; Tada Y; Nemoto O; Rozzo SJ; Kawamura M; Ohtsuki M
    J Dermatol; 2021 Jun; 48(6):844-852. PubMed ID: 33523513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical implications and predictive values of early PASI responses to tildrakizumab in patients with moderate-to-severe plaque psoriasis.
    Feldman SR; Merola JF; Pariser DM; Zhang J; Zhao Y; Mendelsohn AM; Gottlieb AB
    J Dermatolog Treat; 2022 May; 33(3):1670-1675. PubMed ID: 33678106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of tildrakizumab by patient demographic and disease characteristics across a phase 2b and 2 phase 3 trials in patients with moderate-to-severe chronic plaque psoriasis.
    Poulin Y; Ramon M; Rosoph L; Weisman J; Mendelsohn AM; Parno J; Rozzo SJ; Lee P
    J Eur Acad Dermatol Venereol; 2020 Jul; 34(7):1500-1509. PubMed ID: 31919889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tildrakizumab for moderate-to-severe plaque psoriasis in Chinese patients: A 12-week randomized placebo-controlled phase III trial with long-term extension.
    Yu C; Geng S; Yang B; Deng Y; Li F; Kang X; Bi M; Zhang F; Zhao Y; Pan W; Tian Z; Xu J; Zhang Z; Yu N; Duan X; Guo S; Sun Q; Li W; Tao J; Liu Z; Yin Y; Wang G
    Chin Med J (Engl); 2024 May; 137(10):1190-1198. PubMed ID: 38192233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials.
    Blauvelt A; Reich K; Lebwohl M; Burge D; Arendt C; Peterson L; Drew J; Rolleri R; Gottlieb AB
    J Eur Acad Dermatol Venereol; 2019 Mar; 33(3):546-552. PubMed ID: 30242918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies.
    Gottlieb AB; Lacour JP; Korman N; Wilhelm S; Dutronc Y; Schacht A; Erickson J; Zhang L; Mallbris L; Gerdes S
    J Eur Acad Dermatol Venereol; 2017 Apr; 31(4):679-685. PubMed ID: 27696577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis.
    Cai L; Jiang C; Zhang G; Fang H; Wang J; Li Y; Xu H; Xiao R; Ding Y; Huang K; Zhang C; Zhang L; Chen B; Duan X; Pan W; Han G; Chen R; Liu L; Zhang S; Tao J; Pang X; Yu J; Wang H; Zhao Y; Li C; Kang X; Qin L; Zhu X; Su J; Li S; Yang C; Feng W; Lei T; Jiang S; Fang R; Lin M; Lu Q; Xu C; Wang W; Zhang J
    Br J Dermatol; 2024 Aug; 191(3):336-343. PubMed ID: 38366639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3).
    Menter A; Warren RB; Langley RG; Merola JF; Kerr LN; Dennehy EB; Shrom D; Amato D; Okubo Y; Reich K
    J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1686-1692. PubMed ID: 28322474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension.
    Reich K; Ortonne JP; Gottlieb AB; Terpstra IJ; Coteur G; Tasset C; Mease P
    Br J Dermatol; 2012 Jul; 167(1):180-90. PubMed ID: 22413944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tildrakizumab: A Review in Moderate-to-Severe Plaque Psoriasis.
    Frampton JE
    Am J Clin Dermatol; 2019 Apr; 20(2):295-306. PubMed ID: 30924030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.